Search
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnAs a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316] Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnRifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent comp...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalMajor depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was ap...
Categories: NMDA Receptor Antagonists, Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalElagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Adm...
Categories: Gonadotropin Releasing Hormone Receptor Antagonists, Cytochrome P-450 SubstratesTelotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the n...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates